Prostaglandin-induced VASP phosphorylation controls alpha II-spectrin breakdown in apoptotic cells

Standard

Prostaglandin-induced VASP phosphorylation controls alpha II-spectrin breakdown in apoptotic cells. / Benz, Peter M; Feller, Stephan M; Sickmann, Albert; Walter, Ulrich; Renné, Thomas.

In: INT IMMUNOPHARMACOL, Vol. 8, No. 2, 01.02.2008, p. 319-24.

Research output: SCORING: Contribution to journalSCORING: Journal articleResearchpeer-review

Harvard

APA

Vancouver

Bibtex

@article{755f66797f6f4af5b99ddd374069bf9f,
title = "Prostaglandin-induced VASP phosphorylation controls alpha II-spectrin breakdown in apoptotic cells",
abstract = "In pathological conditions, the inflammatory mediator prostaglandin E2 (PGE2) has been shown to induce apoptosis through a cAMP-dependent pathway. However, underlying mechanisms have remained illusive. Irrespective whether apoptosis is induced by the intrinsic or extrinsic pathway, the cysteine protease caspase-3 becomes activated and cleaves many key proteins including spectrins. Cleavage of the plasma membrane-associated spectrins leads to cell shrinkage, membrane blebbing, the formation of apoptotic bodies, and irreversible cell death. Recently, we identified a novel interaction between alpha II-spectrin and vasodilator-stimulated phosphoprotein (VASP), which is abrogated by the cAMP-dependent protein kinase (PKA)-mediated phosphorylation of VASP. In the present study we investigated whether VASP binding to alpha II-spectrin affects spectrin breakdown in PGE2-induced apoptosis. PGE2 dose- and time-dependently triggered VASP phosphorylation. Following induction of apoptosis, caspase-3-mediated alpha II-spectrin breakdown and membrane blebbing were markedly delayed in wild-type as compared to VASP-deficient endothelial cells. This suggests that VASP binding to alpha II-spectrin attenuates alpha II-spectrin cleavage in apoptotic cells and that PGE2-induced VASP phosphorylation regulates this process. Our findings may therefore provide the molecular basis for PGE2-induced apoptosis in pathological events.",
keywords = "Animals, Apoptosis, Caspase 3, Cell Adhesion Molecules, Dinoprostone, Dose-Response Relationship, Drug, Mice, Microfilament Proteins, Phosphoproteins, Phosphorylation, Spectrin",
author = "Benz, {Peter M} and Feller, {Stephan M} and Albert Sickmann and Ulrich Walter and Thomas Renn{\'e}",
year = "2008",
month = feb,
day = "1",
doi = "10.1016/j.intimp.2007.10.004",
language = "English",
volume = "8",
pages = "319--24",
journal = "INT IMMUNOPHARMACOL",
issn = "1567-5769",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Prostaglandin-induced VASP phosphorylation controls alpha II-spectrin breakdown in apoptotic cells

AU - Benz, Peter M

AU - Feller, Stephan M

AU - Sickmann, Albert

AU - Walter, Ulrich

AU - Renné, Thomas

PY - 2008/2/1

Y1 - 2008/2/1

N2 - In pathological conditions, the inflammatory mediator prostaglandin E2 (PGE2) has been shown to induce apoptosis through a cAMP-dependent pathway. However, underlying mechanisms have remained illusive. Irrespective whether apoptosis is induced by the intrinsic or extrinsic pathway, the cysteine protease caspase-3 becomes activated and cleaves many key proteins including spectrins. Cleavage of the plasma membrane-associated spectrins leads to cell shrinkage, membrane blebbing, the formation of apoptotic bodies, and irreversible cell death. Recently, we identified a novel interaction between alpha II-spectrin and vasodilator-stimulated phosphoprotein (VASP), which is abrogated by the cAMP-dependent protein kinase (PKA)-mediated phosphorylation of VASP. In the present study we investigated whether VASP binding to alpha II-spectrin affects spectrin breakdown in PGE2-induced apoptosis. PGE2 dose- and time-dependently triggered VASP phosphorylation. Following induction of apoptosis, caspase-3-mediated alpha II-spectrin breakdown and membrane blebbing were markedly delayed in wild-type as compared to VASP-deficient endothelial cells. This suggests that VASP binding to alpha II-spectrin attenuates alpha II-spectrin cleavage in apoptotic cells and that PGE2-induced VASP phosphorylation regulates this process. Our findings may therefore provide the molecular basis for PGE2-induced apoptosis in pathological events.

AB - In pathological conditions, the inflammatory mediator prostaglandin E2 (PGE2) has been shown to induce apoptosis through a cAMP-dependent pathway. However, underlying mechanisms have remained illusive. Irrespective whether apoptosis is induced by the intrinsic or extrinsic pathway, the cysteine protease caspase-3 becomes activated and cleaves many key proteins including spectrins. Cleavage of the plasma membrane-associated spectrins leads to cell shrinkage, membrane blebbing, the formation of apoptotic bodies, and irreversible cell death. Recently, we identified a novel interaction between alpha II-spectrin and vasodilator-stimulated phosphoprotein (VASP), which is abrogated by the cAMP-dependent protein kinase (PKA)-mediated phosphorylation of VASP. In the present study we investigated whether VASP binding to alpha II-spectrin affects spectrin breakdown in PGE2-induced apoptosis. PGE2 dose- and time-dependently triggered VASP phosphorylation. Following induction of apoptosis, caspase-3-mediated alpha II-spectrin breakdown and membrane blebbing were markedly delayed in wild-type as compared to VASP-deficient endothelial cells. This suggests that VASP binding to alpha II-spectrin attenuates alpha II-spectrin cleavage in apoptotic cells and that PGE2-induced VASP phosphorylation regulates this process. Our findings may therefore provide the molecular basis for PGE2-induced apoptosis in pathological events.

KW - Animals

KW - Apoptosis

KW - Caspase 3

KW - Cell Adhesion Molecules

KW - Dinoprostone

KW - Dose-Response Relationship, Drug

KW - Mice

KW - Microfilament Proteins

KW - Phosphoproteins

KW - Phosphorylation

KW - Spectrin

U2 - 10.1016/j.intimp.2007.10.004

DO - 10.1016/j.intimp.2007.10.004

M3 - SCORING: Journal article

C2 - 18182247

VL - 8

SP - 319

EP - 324

JO - INT IMMUNOPHARMACOL

JF - INT IMMUNOPHARMACOL

SN - 1567-5769

IS - 2

ER -